HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Featured / Real World Evidence Poised to Tip the Balance in Fight Against COVID-19 Through Aetion’s Series B Platform

Real World Evidence Poised to Tip the Balance in Fight Against COVID-19 Through Aetion’s Series B Platform

Tech startup Aetion has added US$19 million to their real-world evidence platform Series B, bringing their round to US$82 million. Aetion believes Series B can give an earlier and more expansive look into treatments for COVID-19. While scientists turned to real-world data early in the pandemic, results have been mixed—the most notable example being the flawed studies of hydroxychloroquine. Speaking on the challenges of using real-world data during the pandemic, Yale cardiologist and health outcomes researcher Harlan Krumholz said such analyses had “awesome potential” but scientists still need to discriminate between good analyses and bad ones. “To date, there are few examples [where] these types of studies have tipped the balance,” Krumholz, who directs Yale’s center for outcomes research and evaluation, said via email

Aetion is currently planning to use real world data and Series B to help vaccine makers with post-approval monitoring to ensure vaccine safety. ”You can imagine that these vaccines are new, and anytime something is new there is no precedent and data could be collected in different ways, depending on the health system, depending on who’s administering the vaccine, as an example, where you are geographically. And all of that has implications on the real world data.” Aetion CEO Carolyn Magill said. Find out more about Aetion and Series B here.

(Source: Jason Mast, Endpoints News, August 26, 2020)



You might also be interested in:

  • Stanford Center for Health Education Launches Online Program… 08/11/2020
  • Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
  • What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
  • Join Aetion’s science leaders for a Q&A during ICPE All Access 09/21/2020
  • Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
  • Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
  • Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute